Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorErasmus Medical Center

About this trial

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.

In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.

The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.

In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.

The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

Eligibility criteria

Qualifiers

Thymoma A

Thymoma AB

Thymoma B1

Thymoma B2

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Artificial Intelligence Diagnostics
  • Recurrence Prediction Tool

Treatment groups

1,020 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Erasmus Medical Center

Lead sponsor

Maastro Clinic, The Netherlands

Collaborator

Hospices Civils de Lyon

Collaborator